SCHEMBL7600329

SCHEMBL7600329

CN1C(=N)NC(c2ccccc2)(c2cccc(NC(=O)Cc3ccccc3)c2)C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.48
MEN1 O00255 6/20 0.48
POLB P06746 3/20 0.48
ALDH1A1 P00352 4/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
PKM P14618 1/20 0.47
XBP1 P17861 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
CCR6 P51684 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
USP2 O75604 2/20 0.46
EPHX2 P34913 1/20 0.45
KDM4E B2RXH2 2/20 0.44
BLM P54132 1/20 0.44
LMNA P02545 2/20 0.44
GAA P10253 1/20 0.43
CFD P00746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7565056 0.88 CA12 (0.47) KMT2AMEN1POLBMAPTHPGD
SCHEMBL7602105 0.87 MEN1 (0.46) KMT2AMEN1POLBMAPTSMN1; SMN2
SCHEMBL7564962 0.86 KMT2A (0.45) KMT2AMEN1POLBALDH1A1NPSR1
SCHEMBL7605877 0.85 KMT2A (0.46) KMT2AMEN1POLBMAPTSMN1; SMN2
SCHEMBL7573453 0.85 KMT2A (0.51) KMT2AMEN1POLBALDH1A1MAPT
SCHEMBL7601912 0.84 KCNK9 (0.48) KMT2AMEN1POLBHPGD
SCHEMBL2970429 0.84 POLB (0.39) KMT2AMEN1POLBHPGDSMN1; SMN2
SCHEMBL7604873 0.83 KMT2A (0.51) KMT2AMEN1POLBALDH1A1MAPT
SCHEMBL7539733 0.83 BACE1 (0.50) KMT2AMEN1POLBALDH1A1MAPT
SCHEMBL7601370 0.82 MEN1 (0.48) KMT2AMEN1POLBALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829036-B2 Heterocyclic aspartyl protease inhibitors MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
US-20120276118-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS PHARMACOPEIA INC. (US) 2012-11-01 US disclosed
US-20120276118-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS PHARMACOPEIA INC. (US) 2012-11-01 US disclosed
US-20120231017-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS PHARMACOPEIA INC. (US) 2012-09-13 US disclosed
US-20120231017-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS PHARMACOPEIA INC. (US) 2012-09-13 US disclosed
US-8183252-B2 Heterocyclic aspartyl protease inhibitors SCHERING CORPORATION (US) 2012-05-22 US disclosed
US-8183252-B2 Heterocyclic aspartyl protease inhibitors SCHERING CORPORATION (US) 2012-05-22 US disclosed
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION 2010-11-18 US disclosed
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS CHRM1, CHRM2, PRSS1 KMT2A 4458/4885MEN1 1192/4885POLB 2893/4885
US-20120276118-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS BACE1, PRSS1, TMPRSS11D KMT2A 3390/4885MEN1 364/4885POLB 2976/4885
US-20120231017-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS BACE1, PRSS1, TMPRSS11D KMT2A 3390/4885MEN1 364/4885POLB 2976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.